Please Wait...

CXCL13 // C-X-C motif chemokine 13

Biomarker Therapeutic Areas: 
Biomarker Matrices: 

CXCL13 (also known as BCA-1 or BLC) is a 10.46kDa protein of 88 residues. Its receptor, CXCR5, is expressed by TFH cells in the follicle (TFH outside the follicle do not express CXCR5). For example, CXCR5 is expressed in the TFH cells which help B cells to differentiate in long lived plasma cells (Tangye et al., 2013).

Blocking the internalization of CXCR5 in mouse, with an anti-CXCL13 antibody, results in impairment of B cell homing in secondary lymphoid organ. It also attenuates symptoms in a model of autoimmune encephalomyelitis (Klimatcheva et al., 2015).

Elevated levels of CXCL13 in serum are detected in several inflammatory diseases such as rheumatoid arthritis, primary Sjörgren’s syndrome and for neuroinflammation (Alvarez et al., 2013; Jones et al., 2014; Kowarik et al., 2012; Nocturne et al., 2015).

 

CXCL13 assay is a solid phase enzyme linked immunoassay which has been validated in the laboratory for measurement in human serum.

 

Alvarez, E., Piccio, L., Mikesell, R.J., Klawiter, E.C., Parks, B.J., Naismith, R.T., and Cross, A.H. (2013). CXCL13 is a Biomarker of Inflammation in Multiple Sclerosis, Neuromyelitis Optica, and Other Neurological Conditions. Mult. Scler. Houndmills Basingstoke Engl. 19, 1204–1208.

Jones, J.D., Hamilton, B.J., Challener, G.J., de Brum-Fernandes, A.J., Cossette, P., Liang, P., Masetto, A., Ménard, H.A., Carrier, N., Boyle, D.L., et al. (2014). Serum C-X-C motif chemokine 13 is elevated in early and established rheumatoid arthritis and correlates with rheumatoid factor levels. Arthritis Res. Ther. 16, R103.

Klimatcheva, E., Pandina, T., Reilly, C., Torno, S., Bussler, H., Scrivens, M., Jonason, A., Mallow, C., Doherty, M., Paris, M., et al. (2015). CXCL13 antibody for the treatment of autoimmune disorders. BMC Immunol. 16, 6.

Kowarik, M.C., Cepok, S., Sellner, J., Grummel, V., Weber, M.S., Korn, T., Berthele, A., and Hemmer, B. (2012). CXCL13 is the major determinant for B cell recruitment to the CSF during neuroinflammation. J. Neuroinflammation 9, 93.

Nocturne, G., Seror, R., Fogel, O., Belkhir, R., Boudaoud, S., Saraux, A., Larroche, C., Le Guern, V., Gottenberg, J.E., and Mariette, X. (2015). CXCL13 and CCL11 serum levels and lymphoma and disease activity in primary Sjögren Syndrome: CXCL13, CCL11 and disease activity in pSS. Arthritis Rheumatol. n/a – n/a.

Tangye, S.G., Ma, C.S., Brink, R., and Deenick, E.K. (2013). The good, the bad and the ugly — TFH cells in human health and disease. Nat. Rev. Immunol. 13, 412–426.

Leader in Clinical Trial
Management Solutions

Successful clinical trials require the ability to see key details and uncover hidden insights. Bioclinica utilizes science and technology to bring clarity to clinical trials, helping companies to develop new life-improving therapies more efficiently and safely.

Integration of #eTMF and #CTMS eliminates redundancies, improves workflows & enables greater study control. Join th… https://t.co/1917MtlAsA
Bioclinica (6 days ago)
Thinking of building a study in-house? Here are the 5 things you should think about before starting a DIY study bui… https://t.co/xzZWQOm49S
Bioclinica (2 weeks ago)
Integration of #eTMF and #CTMS eliminates redundancies, improves workflows & enables greater study control. Join th… https://t.co/Hoqf18zcPF
Bioclinica (2 weeks ago)
Your #IRT should not be the limiting factor during study start-up. The core features of Bioclinica's IRT agile plat… https://t.co/kitdsWvJ2S
Bioclinica (2 weeks ago)
Presenting Bioclinica CTMS: a rapid startup #CTMS that takes 2 weeks to implement, rather than months. Bioclinica C… https://t.co/tclYFoJx2z
Bioclinica (3 weeks ago)
Improve doc & study mgmt. across all studies by integrating #eTMF & #CTMS. In this webinar, Bioclinica &… https://t.co/UyoQyJVDah
Bioclinica (3 weeks ago)